Company news

Candel Therapeutics, Inc. news in 2023

Candel Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

December 11, 2023

Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409

November 27, 2023

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

November 8, 2023

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

November 3, 2023

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

November 2, 2023

Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

October 17, 2023

Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting

September 26, 2023

Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

September 25, 2023

Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024

June 12, 2023

Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors

June 7, 2023

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 18, 2023

Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 10, 2023

Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO

May 1, 2023

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer

April 16, 2023

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

March 29, 2023

Decks in 2023